T790M, also known as Thr790Met, is a gatekeeper mutation of the epidermal growth factor receptor (EGFR). The mutation substitutes a threonine (T) with a methionine (M) at position 790 of exon 20, affecting the ATP binding pocket of the EGFR kinase domain. Threonine is a small polar amino acid; methionine is a larger nonpolar amino acid.
Over 50% of acquired resistance to EGFR tyrosine kinase inhibitors (TKI) is caused by a mutation in the ATP binding pocket of the EGFR kinase domain involving substitution of a small polar threonine residue with a large nonpolar methionine residue, T790M.
In November 2015, the US FDA granted accelerated approval to osimertinib (Tagrisso) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, which progressed on or after EGFR TKI therapy.
I pretend to sleep while she cries at night
Then slowly dries her eyes
Vacant are the words of mine
That say we are alright
I don't want, don't want to be
Your hate and misery
But I want to be your crutch and I want to be your thing
In this eternal un-ending
Hold on tight but don't hold me down
Stay all night if you wanna
Do your worst, your worst to me
No one will ever hear you
So let me get this straight
I'll take a minute if I may
And try to take it all
Take it away for you
Black and blue with residue
Your open heart and the untrue
Try to let us go
Another night without
I don't want, don't want to be
Your hate and misery
But I want to be your crutch and I want to be your thing
In this eternal un-ending
Hold on tight but don't hold me down
Stay all night if you wanna
Do your worst, your worst to me